Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (TN2012000081) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

Office : Tunisia
Application Number: P2012000081 Application Date: 17.02.2012
Publication Number: 2012000081 Publication Date: 19.09.2013
Publication Kind : A1
Prior PCT appl.: Application Number:PCTUS2010046930 ; Publication Number: Click to see the data
IPC:
A61K 31/506
A61P 35/00
C07D 401/14
C07D 403/04
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
Applicants: IRM LLC
NORVARTIS AG
Inventors: HUANG SHENLIN
JIN XIANMING
LIU ZUOSHENG
POON DANIEL
TELLEW JOHN
WAN YONGQIN
WANG XING
XIE YONGPING
Priority Data:
Title: (EN) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
Abstract:
(EN)

The invention provides a novel class of compounds of formula 1, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.


Also published as:
RSP-2014/0430UAa201203042SG178351IL218084EP2470526DOP2012000051
JP2013503186CN102725283CA2771775EA201200373EP2727918ES2492499
KR1020120062839NZ598924DK2470526AU2010286569VN30470ID2012/03594
TH140028IN2469/DELNP/2012WO/2011/025927